Newsroom

Download PDF Refocused Resources Projected to Save $100 Million over Three Years Progress Made toward Commercialization of Tivozanib CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 30, 2012– AVEO Oncology (NASDAQ: AVEO) today announced a strategic restructuring designed to optimize resources and reduce expenses to ensure AVEO is well positioned for a successful launch of tivozanib in renal cell carcinoma (RCC) and continued development

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 23, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s third quarter ended September 30, 2012 will be released before the market opens on Tuesday, October 30, 2012. The AVEO management team will host a conference call discussing the company’s financial results and recent updates on Tuesday, October 30 at 10:00 a.m.

Download PDF Ficlatuzumab Phase 1 Pharmacodynamic Data Also Presented CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 1, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that detailed results from an exploratory, randomized Phase 2 study evaluating the combination of ficlatuzumab, the company’s HGF inhibitory antibody, and gefitinib compared to gefitinib monotherapy in previously untreated Asian subjects with non-small cell lung

Download PDF First Patient Enrolled in TAURUS Patient Preference Study Posters 795PD, 796PD and 892TiP CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Oct. 1, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced new data from the Phase 3 TIVO-1 trial (TIvozanib Versus sOrafenib in 1st line advanced RCC) demonstrating the safety and tolerability profile of tivozanib versus sorafenib in the first line setting

Download PDF CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)–Sep. 28, 2012– AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE:4503) today announced that AVEO has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tivozanib in patients with advanced renal cell carcinoma (RCC). Tivozanib is designed to target the vascular endothelial growth factor (VEGF) pathway, a clinically

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 20, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that new clinical data on its lead product candidate tivozanib, partnered with Astellas Pharma Inc. (TSE: 4503), as well as its HGF inhibitory antibody ficlatuzumab will be presented at the European Society of Medical Oncology (ESMO) 2012 Congress in Vienna, Austria, September 28 – October 2, 2012. “At this year’s ESMO, investigators will present

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 13, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the UBS Annual Global Life Sciences Conference on Thursday, September 20, 2012 at 2:00 p.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at

Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 3, 2012– AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Monday, September 10, 2012 at 10:35 a.m. (ET) in New York City. A live webcast of AVEO’s presentation can be accessed by visiting the investors section of the company’s website at investor.aveooncology.com. A replay